Compass Therapeutics(CMPX) - 2025 Q4 - Annual Results

Financial Position - As of December 31, 2025, Compass Therapeutics, Inc. estimated cash, cash equivalents, and marketable securities to be approximately $209 million[6] - The reported amount is unaudited and preliminary, subject to changes upon completion of financial closing procedures[6] - The financial statements for the year ended December 31, 2025, will reflect the finalized amounts[6] Corporate Information - The company provided a corporate update in a press release dated January 6, 2026[5] - The company is listed on the NASDAQ Capital Market under the trading symbol CMPX[2] - The company’s principal executive offices are located in Boston, Massachusetts[1] Company Classification and Compliance - The report indicates that Compass Therapeutics is not currently classified as an emerging growth company[3] - The company has not elected to use the extended transition period for complying with new or revised financial accounting standards[3] Performance and Future Guidance - The report does not provide specific performance metrics or future guidance at this time[4] - There are no details on new products, technologies, market expansion, or mergers and acquisitions in the current report[4]